NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MitoImmune Therapeutics

MitoImmune Therapeutics

Private
SeoulHealthcare & Life Scienceshttps://mitoimmune.com/

Last Round

Series B

Extension

Sep 25, 2023

Total Funding Raised

$38.81M

Company Overview

MitoImmune Therapeutics is a biotechnology company that develops innovative drugs targeting mitochondrial dysfunction and regulated necrotic cell death.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymitochondrial dysfunctionferroptosisreactive oxygen speciesROS scavengerblood-brain barrierBBB penetrationclinical-stage biotechoral mucositissmall-molecule drugneurodegenerative diseasedrug licensingbiotech startuptherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MitoImmune Therapeutics Comparables

Compare MitoImmune Therapeutics with similar companies based on industry and business-model similarity.

MitoImmune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Morningside
78%
SeaBeLife
77%
Pretzel Therapeutics
77%

MitoImmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionSep 25, 2023
Series BFeb 26, 2021
Series AApr 1, 2019

MitoImmune Therapeutics Investors

Notable investors and investment history

MitoImmune Therapeutics investors
InvestorRounds
BNH INVESTMENTSeries A, Series B
SL InvestmentSeries A, Series B
KB InvestmentSeries A, Series B
Orion Capital ManagementSeries B
K-Ground VenturesSeries B Extension
GTO InvestmentSeries B
CJ InvestmentSeries B

MitoImmune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MitoImmune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MitoImmune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range5
Year Founded2018
Last FundingSep 25, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.